Novartis AG

Swiss Stock Exchange:NOVN.SW

Location

Market Cap

USD 236.93 B

Share Price

USD 119.96

Avg Daily Volume

4,098,771

Change (1 day)

1.87%

Change (1 year)

12.33%

Change (YTD)

22.30%

Novartis AG Free Cash Flow for the year ending December 31, 2024: USD 13.80 B

Novartis AG Free Cash Flow is USD 13.80 B for the year ending December 31, 2024, a 17.94% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • Novartis AG Free Cash Flow for the year ending December 31, 2023 was USD 11.71 B, a 1.21% change year over year.
  • Novartis AG Free Cash Flow for the year ending December 31, 2022 was USD 11.56 B, a -4.42% change year over year.
  • Novartis AG Free Cash Flow for the year ending December 31, 2021 was USD 12.10 B, a 9.35% change year over year.
  • Novartis AG Free Cash Flow for the year ending December 31, 2020 was USD 11.06 B, a -2.67% change year over year.
Key data
Date Free Cash Flow Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities
Market news
Loading...
Swiss Stock Exchange: NOVN.SW

Novartis AG

CEO Dr. Vasant Narasimhan M.D.
IPO Date Aug. 3, 1995
Location Switzerland
Headquarters Lichtstrasse 35
Employees 75,883
Sector 🏥 Health Care
Industries
Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Similar companies

ABBV

AbbVie Inc.

USD 186.79

0.76%

NOVO-B.CO

Novo Nordisk A/S

USD 67.40

-0.61%

RO.SW

Roche Holding AG

USD 346.81

1.67%

ABT

Abbott Laboratories

USD 133.67

-2.71%

AZN.L

AstraZeneca PLC

USD 139.42

-0.41%

MRK

Merck & Co., Inc.

USD 78.83

-1.05%

AMGN

Amgen Inc.

USD 279.11

-0.44%

PFE

Pfizer Inc.

USD 24.24

-0.08%

GILD

Gilead Sciences, Inc.

USD 107.62

1.59%

SAN.PA

Sanofi

USD 96.29

0.40%

VRTX

Vertex Pharmaceuticals Incorporated

USD 443.40

-0.54%

BMY

Bristol-Myers Squibb Company

USD 46.65

-0.06%

4519.T

Chugai Pharmaceutical Co., Ltd.

USD 52.04

-0.89%

GSK.L

GSK plc

USD 19.17

0.64%

CSL.AX

CSL Limited

USD 154.14

-1.86%

REGN

Regeneron Pharmaceuticals, Inc.

USD 521.00

0.14%

MRK.DE

MERCK Kommanditgesellschaft auf Aktien

USD 130.63

1.54%

600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

USD 7.21

-0.69%

4502.T

Takeda Pharmaceutical Company Limited

USD 30.27

0.35%

ALNY

Alnylam Pharmaceuticals, Inc.

USD 318.25

-1.15%

UCB.BR

UCB SA

USD 197.49

0.30%

GEHC

GE HealthCare Technologies Inc.

USD 74.86

2.90%

BAYN.DE

Bayer AG

USD 30.75

-0.14%

2359.HK

WuXi AppTec Co., Ltd.

USD 9.61

-2.55%

068270.KS

Celltrion, Inc.

USD 117.59

0.22%

LH

Laboratory Corporation of America Holdings

USD 256.98

-0.66%

3692.HK

Hansoh Pharmaceutical Group Company Limited

USD 3.70

-0.14%

RPRX

Royalty Pharma plc

USD 35.27

-1.78%

INSM

Insmed Incorporated

USD 101.74

-2.97%

BIIB

Biogen Inc.

USD 126.92

-0.31%

4503.T

Astellas Pharma Inc.

USD 9.70

1.17%

1801.HK

Innovent Biologics, Inc.

USD 9.80

-2.13%

SMMT

Summit Therapeutics Inc.

USD 21.32

0.24%

4507.T

Shionogi & Co., Ltd.

USD 17.52

-0.59%

GMAB.CO

Genmab A/S

USD 206.84

0.92%

NBIX

Neurocrine Biosciences, Inc.

USD 126.71

-0.84%

TORNTPHARM.NS

Torrent Pharmaceuticals Limited

USD 37.60

0.25%

EXEL

Exelixis, Inc.

USD 43.09

-1.01%

RGC

Regencell Bioscience Holdings Limited

USD 20.19

-7.09%

MANKIND.NS

Mankind Pharma Limited

USD 26.88

0.15%

603392.SS

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

USD 8.53

0.36%

9926.HK

Akeso, Inc.

USD 11.66

-3.50%

BMRN

BioMarin Pharmaceutical Inc.

USD 54.10

-0.07%

ASND

Ascendis Pharma A/S

USD 172.95

-0.03%

LUPIN.NS

Lupin Limited

USD 22.50

0.04%

SOBI.ST

Swedish Orphan Biovitrum AB (publ)

USD 29.13

0.10%

IPN.PA

Ipsen S.A.

USD 120.27

0.45%

000963.SZ

Huadong Medicine Co., Ltd

USD 5.62

0.38%

4151.T

Kyowa Kirin Co., Ltd.

USD 16.92

-1.27%

StockViz Staff

June 27, 2025

Any question? Send us an email